Loading patent…
OwnerKaori HARADA, Susumu MUTOinventors
Estimating the term…
A Hunner-type interstitial cystitis therapeutic agent that can selectively inhibit IFN-γ without risk of biological contamination and can be stored at room temperature. Provided is a Hunner-type interstitial cystitis therapeutic agent or a reagent for test and research, includes an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to IFN-γ. A base, X, in the sequence of the DNA oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base may be chemically modified with a low-molecular-weight compound, a medium-molecular-weight compound, a high-molecular-weight compound, a biopolymer, or a biocompatible polymer.
A Hunner-type interstitial cystitis therapeutic agent comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to interferon-γ (IFN-γ).
A therapeutic agent comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:
A reagent for test and research, comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:
Dependencies are inferred from the claim text.